Allos Therapeutics, Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 7 Calls Today's Calls

Call Details Allos Therapeutics, Inc. Earnings Conference Call (Q1 2008) Wed, May 7, 2008, 8:30 am Eastern Listen to the archived event audio About Allos Therapeutics, Inc. (NasdaqGM:ALTH) Allos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule therapeutics for the treatment of cancer. Its lead product candidate, PDX (pralatrexate), is a novel antifolate under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. Its other product candidate is RH1, a targeted chemotherapeutic agent, under evaluation in Phase 1 in patients with advanced solid tumors or non-Hodgkin's Lymphoma. Allos Therapeutics was founded in 1992. It was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in 1994. The company is headquartered in Westminster, Colorado. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings